Advertisement
EVO vs SUPN
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EVO is a StrongBuy and SUPN is a StrongBuy.
EVO in upward trend: price may ascend as a result of having broken its lower Bollinger Band on October 12, 2026
EVO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 30 of 37 cases where EVO's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 81%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where EVO's RSI Oscillator exited the oversold zone, 30 of 40 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 46 of 65 cases where EVO's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 71%.
The Moving Average Convergence Divergence (MACD) for EVO just turned positive on October 20, 2026. Looking at past instances where EVO's MACD turned positive, the stock continued to rise in 26 of 42 cases over the following month. The odds of a continued upward trend are 62%.
Following a +9.86% 3-day Advance, the price is estimated to grow further. Considering data from situations where EVO advanced for three days, in 185 of 274 cases, the price rose further within the following month. The odds of a continued upward trend are 68%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on EVO as a result. In 84 of 101 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EVO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
The Aroon Indicator for EVO entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 1 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 82 (best 1 - 100 worst), indicating slightly worse than average price growth. EVO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 92 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.746) is normal, around the industry mean (11.138). EVO's P/E Ratio (476.190) is considerably higher than the industry average of (-7.600). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.038) among similar stocks. P/S Ratio (0.695) is also within normal values, averaging (178.797).
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EVO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
SUPN in upward trend: price expected to rise as it breaks its lower Bollinger Band on October 14, 2026
SUPN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 26 of 34 cases where SUPN's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 76%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where SUPN's RSI Indicator exited the oversold zone, 20 of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 74%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 45 of 61 cases where SUPN's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 74%.
Following a +8.84% 3-day Advance, the price is estimated to grow further. Considering data from situations where SUPN advanced for three days, in 227 of 314 cases, the price rose further within the following month. The odds of a continued upward trend are 72%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SUPN as a result. In 71 of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 73%.
The Moving Average Convergence Divergence Histogram (MACD) for SUPN turned negative on October 14, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 53 similar instances when the indicator turned negative. In 36 of the 53 cases the stock turned lower in the days that followed. This puts the odds of success at 68%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SUPN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 64%.
The Aroon Indicator for SUPN entered a downward trend on September 24, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 40 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.327) is normal, around the industry mean (11.138). P/E Ratio (-21.464) is within average values for comparable stocks, (-7.600). Projected Growth (PEG Ratio) (0.900) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.038) among similar stocks. P/S Ratio (2.863) is also within normal values, averaging (178.797).
The Tickeron Profit vs. Risk Rating rating for this company is 57 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 71 (best 1 - 100 worst), indicating slightly worse than average price growth. SUPN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
EVO | SUPN | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 74 | 12 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 92 Overvalued | 40 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 57 | |
SMR RATING 1..100 | 96 | 94 | |
PRICE GROWTH RATING 1..100 | 82 | 71 | |
P/E GROWTH RATING 1..100 | 1 | 98 | |
SEASONALITY SCORE 1..100 | 85 | 90 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
SUPN's Valuation (40) in the Pharmaceuticals Other industry is somewhat better than the same rating for EVO (92) in the null industry. This means that SUPN’s stock grew somewhat faster than EVO’s over the last 12 months.
SUPN's Profit vs Risk Rating (57) in the Pharmaceuticals Other industry is somewhat better than the same rating for EVO (100) in the null industry. This means that SUPN’s stock grew somewhat faster than EVO’s over the last 12 months.
SUPN's SMR Rating (94) in the Pharmaceuticals Other industry is in the same range as EVO (96) in the null industry. This means that SUPN’s stock grew similarly to EVO’s over the last 12 months.
SUPN's Price Growth Rating (71) in the Pharmaceuticals Other industry is in the same range as EVO (82) in the null industry. This means that SUPN’s stock grew similarly to EVO’s over the last 12 months.
EVO's P/E Growth Rating (1) in the null industry is significantly better than the same rating for SUPN (98) in the Pharmaceuticals Other industry. This means that EVO’s stock grew significantly faster than SUPN’s over the last 12 months.
| EVO | SUPN | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 75% | 2 days ago 74% |
| Stochastic ODDS (%) | 2 days ago 71% | 2 days ago 74% |
| Momentum ODDS (%) | 2 days ago 83% | 2 days ago 73% |
| MACD ODDS (%) | 2 days ago 62% | 2 days ago 68% |
| TrendWeek ODDS (%) | 2 days ago 67% | 2 days ago 72% |
| TrendMonth ODDS (%) | 2 days ago 62% | 2 days ago 65% |
| Advances ODDS (%) | 2 days ago 68% | 3 days ago 72% |
| Declines ODDS (%) | 7 days ago 80% | 7 days ago 64% |
| BollingerBands ODDS (%) | 2 days ago 81% | 2 days ago 76% |
| Aroon ODDS (%) | 2 days ago 70% | 2 days ago 71% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
EVO’s FA Score shows that 1 FA rating(s) are green while SUPN’s FA Score has 0 green FA rating(s).
- EVO’s FA Score: 1 green, 4 red.
- SUPN’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
EVO’s TA Score shows that 5 TA indicator(s) are bullish while SUPN’s TA Score has 4 bullish TA indicator(s).
- EVO’s TA Score: 5 bullish, 3 bearish.
- SUPN’s TA Score: 4 bullish, 4 bearish.
Price Growth
EVO (@Pharmaceuticals: Generic) experienced а +9.47% price change this week, while SUPN (@Pharmaceuticals: Generic) price change was +2.56% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -2.82%. For the same industry, the average monthly price growth was -9.61%, and the average quarterly price growth was +10.18%.
Reported Earning Dates
EVO is expected to report earnings on Nov 05, 2026.
SUPN is expected to report earnings on Oct 29, 2026.
Industries' Descriptions
@Pharmaceuticals: Generic (-2.82% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
Advertisement
SUPN and
Correlation & Price change
A.I.dvisor indicates that over the last year, SUPN has been loosely correlated with PRGO. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if SUPN jumps, then PRGO could also see price increases.
| Ticker / NAME | Correlation To SUPN | 1D Price Change % | ||
|---|---|---|---|---|
| SUPN | 100% | -0.05% | ||
| PRGO - SUPN | 48% Loosely correlated | -1.61% | ||
| INDV - SUPN | 38% Loosely correlated | +0.06% | ||
| ELAN - SUPN | 33% Loosely correlated | -0.66% | ||
| ANIP - SUPN | 33% Poorly correlated | -0.59% | ||
| XERS - SUPN | 30% Poorly correlated | -3.10% | ||
More | ||||